• 제목/요약/키워드: CONP01

검색결과 4건 처리시간 0.018초

랫드에서 CONP01에 대한 4주 반복투여 독성연구 (Four-Week Repeated-Dose Toxicity Studies of CONP01 in Rats)

  • 홍동호;장호송;김광호;길기현;김재민;한명규;배진숙;김남두;이현걸;이정숙;이선경;박찬구;송시환
    • Toxicological Research
    • /
    • 제20권4호
    • /
    • pp.349-357
    • /
    • 2004
  • This study was performed to evaluate repeated-dose toxicities of CONP01 in Sprague-Dawley rats. CONP01, a new antiarthritic agent was administered orally to rats at dose levels of 0, 125, 500 and 2,000 mg/kg/day for 4 weeks. In present study, there were no dose response changes in mortality, clinical signs, body weight changes, food and water consumption, ophthalmoscopy, organ weights, urine analysis, hematological findings, and biochemical examination of all animals treated with CONP01. Gross and histopathological findings revealed no evidence of specific toxicity related to CONP01. These result suggest that no observed adverse effect level (NOAEL) of CONP01 may be over 2,000 mg/kg in rats.

새로운 관절염 치료제 CONP01의 생식독성연구: 랫드 배 · 태자 발생시험 (Reproductive Toxicity Study of CONP01, a New Antiarthritic Agent: Developmental Study in Rats)

  • 이정숙;홍동호;김광호;장호송;길기현;한명규;양현주;배진숙;김남두;송시환
    • Toxicological Research
    • /
    • 제21권1호
    • /
    • pp.23-29
    • /
    • 2005
  • A developmental study of CONP01, a new antiarthritic agent, was conducted in Sprague-Dawley rats. Dosage of CONP01 0, 111, 333, and 1000 mg/kg/day were administered to dams orally from day 6 to day 16 of gestation. Two-third of dams per group were subjected to caesarean section on day day 20 of pregnancy for examination of their fetuses, and the remaining one-third of dams per group were allowed to deliver naturally for postnatal examination of their offspring. There was no change in the dams body weights, food consumptions, specific clinical sings and gross findings. There was significant decrease only in the absolute and relative weights of right ovary in 111 mg/kg treatment group, when compared with the vehicle control, whereas other organ weights were not changed. Moreover, no increase in the frequencies of external, visceral and skeletal malformation of fetuses were observed in the treated groups. These results suggest that the oral NOAEL (no observed adverse effect level) of CONP01 may be over 1,000 mg/kg in dams and fetuses of rats.